Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Current Liabilities: 2020-2024

Historic Total Current Liabilities for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $81.0 million.

  • Arcutis Biotherapeutics' Total Current Liabilities fell 42.14% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year decrease of 42.14%. This contributed to the annual value of $81.0 million for FY2024, which is 73.59% up from last year.
  • As of FY2024, Arcutis Biotherapeutics' Total Current Liabilities stood at $81.0 million, which was up 73.59% from $46.7 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Total Current Liabilities registered a high of $81.0 million during FY2024, and its lowest value of $22.6 million during FY2020.
  • Its 3-year average for Total Current Liabilities is $55.2 million, with a median of $46.7 million in 2023.
  • Data for Arcutis Biotherapeutics' Total Current Liabilities shows a peak YoY spiked of 73.59% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Arcutis Biotherapeutics' Total Current Liabilities stood at $22.6 million in 2020, then skyrocketed by 47.45% to $33.3 million in 2021, then rose by 13.45% to $37.8 million in 2022, then climbed by 23.44% to $46.7 million in 2023, then soared by 73.59% to $81.0 million in 2024.